ODI Pharma AB (ODI.ST)
SEK 2.76
(-8.0%)
SEK 2.76
(-8.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 22.44 Million SEK | 15996.09% |
| 2022 | 139.45 Thousand SEK | -55.44% |
| 2021 | 312.93 Thousand SEK | 0.0% |
| 2020 | - SEK | 0.0% |
| 2019 | - SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 Q4 | 7.54 Million SEK | -45.55% |
| 2023 Q3 | 13.85 Million SEK | 1179179.91% |
| 2023 Q1 | 528.2 Thousand SEK | 1829.59% |
| 2023 FY | 22.44 Million SEK | 15996.09% |
| 2023 Q2 | 1175.00 SEK | -99.78% |
| 2022 FY | 139.45 Thousand SEK | -55.44% |
| 2022 Q4 | 27.37 Thousand SEK | 153.44% |
| 2022 Q3 | 10.8 Thousand SEK | -85.26% |
| 2022 Q2 | 73.27 Thousand SEK | 161.64% |
| 2022 Q1 | 28 Thousand SEK | 96.77% |
| 2021 Q1 | - SEK | 0.0% |
| 2021 FY | 312.93 Thousand SEK | 0.0% |
| 2021 Q4 | 14.23 Thousand SEK | -80.04% |
| 2021 Q3 | 71.29 Thousand SEK | 0.0% |
| 2020 FY | - SEK | 0.0% |
| 2019 FY | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AcuCort AB | - SEK | -Infinity% |
| AlzeCure Pharma AB (publ) | - SEK | -Infinity% |
| BioGaia AB (publ) | 1.29 Billion SEK | 98.269% |
| Enzymatica AB (publ) | 50.9 Million SEK | 55.903% |
| Enorama Pharma AB (publ) | 1.35 Million SEK | -1552.955% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | - SEK | -Infinity% |
| Moberg Pharma AB (publ) | - SEK | -Infinity% |
| Nanexa AB (publ) | 29.32 Million SEK | 23.459% |
| Newbury Pharmaceuticals AB (publ) | 36.82 Million SEK | 39.05% |
| Orexo AB (publ) | 638.8 Million SEK | 96.486% |
| Probi AB (publ) | 627.68 Million SEK | 96.424% |
| Swedencare AB (publ) | 2.32 Billion SEK | 99.034% |
| Swedish Orphan Biovitrum AB (publ) | 22.12 Billion SEK | 99.899% |
| Toleranzia AB | 50.92 Million SEK | 55.917% |
| Vivesto AB | 1.01 Million SEK | -2111.539% |